{"description":"Adverse event collection started at time of consent and ended when patients moved to follow-up.","eventGroups":[{"deathsNumAffected":26,"deathsNumAtRisk":40,"description":"Patients undergo collection of bone marrow aspirate and blood for high-throughput drug sensitivity assay and mutational analysis using next generation sequencing. Patients and their treating physicians receive the results of the tests. Treatment decisions are then made by the patients and their treating physicians.\n\nBiospecimen Collection: Undergo collection of bone marrow aspirate and blood\n\nHigh Throughput Screening: Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay\n\nLaboratory Biomarker Analysis: Correlative studies","id":"EG000","otherNumAffected":0,"otherNumAtRisk":40,"seriousNumAffected":0,"seriousNumAtRisk":40,"title":"Device Feasibility (High-throughput Assay, Sequencing)"}],"frequencyThreshold":"5","timeFrame":"Adverse event collection started from the time of signing consent until the time at which assay results are provided to the patient and their treating physician, up to 6 weeks post-enrollment."}